Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study - Wikidata - awgldk - TriplyDB

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study

http://www.wikidata.org/entity/Q30544631

about

Targeted therapy for localized non-small-cell lung cancer: a review Pulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials EGFR-TKIs in adjuvant treatment of lung cancer: to give or not to give?Current Status and Development of Traditional Chemotherapy in Non-small Cell Lung Cancer under the Background of Targeted Therapy A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives Medical management of lung cancer: Experience in China Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer 50 Years of progress in the systemic therapy of non-small cell lung cancer Advanced EGFR mutation-positive non-small-cell lung cancer: case report, literature review, and treatment recommendations Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario Incidence and risk of infections associated with EGFR-TKIs in advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.Advances in adjuvant systemic therapy for non-small-cell lung cancer.Research, evidence, and ethics: new technology or grey medicine.The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review.Pre-operative chemotherapy for non-small cell lung carcinoma Adjuvant chemotherapy in patients with completely resected non-small cell lung cancer The challenge of using biomarkers and molecularly targeted drugs to improve cure rate in early stage non-small cell lung cancer EGFR: The Paradigm of an Oncogene-Driven Lung Cancer Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer.Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status.Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy.The Globalization of Cooperative Groups.ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer Have adjuvant tyrosine kinase inhibitors lost their shine?A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer.Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations.Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients.A review of drugs in development for the personalized treatment of head and neck squamous cell carcinoma.Genetic characterization drives personalized therapy for early-stage non-small-cell lung cancer (NSCLC) patients and survivors with metachronous second primary tumor (MST): A case report.Lung cancer in 2013: Refining standard practice and admitting uncertainty.The diagnosis and treatment of brain metastases in EGFR mutant lung cancer.Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.Clinical impact of the new IASLC/ATS/ERS lung adenocarcinoma classification for chest surgeons.Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond.Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors.Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art.

P2860

Q26741441-71F89E94-DACC-4E97-A320-69EE11F1B525 Q26768125-570131AF-80F7-491B-BB97-3B6796C0623F Q26778298-190A1BDC-C785-434B-83CA-1E025CCFFEA5 Q26783432-F1E54FDF-A2A6-48E0-A451-39BB04100538 Q26797297-9EFFBA02-F5A1-4082-99FA-BC7E4CD1288E Q26798257-423B9C62-2BB5-4BDA-BF61-25B44357CC99 Q26851417-2E55B8C5-187D-4A22-A7A5-FFE8ABD2CC54 Q26863742-DF1BB08B-23DE-4AE9-814C-1CF5659397E7 Q27002509-7D699F2A-3A6C-4F2C-A8A3-793286EAD336 Q27014978-6CB9493E-AA9B-4277-931E-07510B52E0D4 Q27021203-B32C7771-21BC-476C-89A1-174FAA94A2BA Q27853213-E5B1751E-6059-4BD6-A58B-DB31D2294209 Q33611088-B8934827-1576-4BB9-8970-283358D0110A Q33710146-4BD046F9-7B28-4615-B51E-B6B338BDED6E Q34031225-2D09D860-ECE9-48C5-9BF6-CB740E666843 Q35065199-34F32390-8D4D-483F-9A69-BD98E11A97FA Q35164824-A680D10C-5E86-4F7A-8360-860C2D1B7B4B Q35200636-17316F56-2BA9-403C-ADDB-F28F863DBCB8 Q35200745-E507A0BD-7EBA-43B2-A565-12083DA61957 Q35290441-A92CD70F-2B81-4C4E-83A6-AE49BDDC2297 Q35619241-7A17BF8E-1DF5-4CD2-A1BA-516FFB455909 Q35631635-9EC6F455-325F-4597-A346-C059B5094B16 Q35681695-D5DA2046-CA3E-4929-B534-CF27D2D2DCDB Q35810510-4A35E6E5-BF00-4569-A96B-1F429EA9A59A Q36119749-9D89F6BE-E80A-4B45-B781-45CD7485577F Q36382373-8817E45D-F820-41ED-B26C-DA44620F1396 Q37165982-4ECBFCF4-E112-4D4D-A6D5-DF6DB953DC84 Q37295447-6697088E-7763-4477-8E44-8D637E555F7C Q37458637-9A2D1CB0-5DF7-4E50-B734-62BA285D375B Q37591935-6A3F1457-D2E7-4D43-BE13-B8CBE68BB2EE Q37669978-1E493BCF-DC94-4BB0-8AE2-8CF3FAF1A69A Q37696841-3F1E59CD-E2DB-4F7A-B3A8-F60C9B0FBD1B Q38180322-5525563A-F707-4610-B522-A2B573CDC613 Q38233179-63849FDD-7A1E-4422-A752-6785FAC009A3 Q38266308-C42B78E3-880F-4975-97B3-F232D2D4C7E4 Q38270567-94F7749D-9A65-471B-9046-1A27E2E0E3C8 Q38390085-34BCE746-3E53-4CDB-A8EA-465348138736 Q38390200-21BC9ED1-37F1-4695-981E-290F299DD997 Q38400481-AF6B6C98-4B65-4382-9325-18D16CE1EB08 Q38419828-06E59B3F-1795-471F-997A-BB919BFAF1F1

P2860

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study

http://www.wikidata.org/entity/Q30544631

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Gefitinib versus placebo in co ...... lts of the NCIC CTG BR19 study

@ast

Gefitinib versus placebo in co ...... lts of the NCIC CTG BR19 study

@en

type

label

Gefitinib versus placebo in co ...... lts of the NCIC CTG BR19 study

@ast

Gefitinib versus placebo in co ...... lts of the NCIC CTG BR19 study

@en

prefLabel

Gefitinib versus placebo in co ...... lts of the NCIC CTG BR19 study

@ast

Gefitinib versus placebo in co ...... lts of the NCIC CTG BR19 study

@en

P1433

Q30544631-75018AF8-AD05-4E70-95F0-4C58391754C5

P1476

Q30544631-3D887580-8E2E-4153-A4E7-699FD8A9414B

P2093

Q30544631-135FFB14-6E3F-4DEC-A16C-A94A758D2556

Q30544631-140DF349-1A2C-4EA6-9B9B-00DE0C054E62

Q30544631-16F6C105-18F2-451D-BB50-D0401AA33B63

Q30544631-195AE630-D26D-47FE-B67E-4C02782A085D

Q30544631-1BA071A3-C133-4C6D-A919-9534B60AA3D8

Q30544631-36D31952-73B2-43B4-9351-91B5E1DB6F66

Q30544631-4F0DE45F-DC30-4B18-8C9A-40B7C1E585A4

Q30544631-62D71A05-8070-48C0-B4C1-1C43C7F19EF8

Q30544631-84ED4F2B-DB52-4857-8F08-2BB61A090B87

Q30544631-91956FF2-46DE-4E63-A298-67AC7D5D1C21

P2860

Q30544631-13A52BFE-BAE4-42E6-A8AB-CCEE43C1E598

Q30544631-1CF0B26A-0417-470A-A557-5B2F3545AED7

Q30544631-1E75CF26-D102-487F-A900-A1DBC415D11B

Q30544631-221E282F-6831-4300-9490-88D766A29915

Q30544631-2C6A11F9-5203-426F-AA56-CFF052EFC85B

Q30544631-2E16DBEF-8C40-4E01-B4ED-281477427BBF

Q30544631-34BA3A09-CC7C-49B0-B7F4-CA3E5D841F5B

Q30544631-3537D952-113E-48A8-AA68-F51552AE267E

Q30544631-3D63AE5B-2914-468A-B81D-24707D9F4D90

Q30544631-4A8157A3-E611-4C66-B795-B7C44C1B8375

P304

Q30544631-C7930A37-E632-4F39-9A8D-A901D7F9193C

P31

Q30544631-BDF97457-7DC4-4ECF-97BE-65C86BE9B56A

P356

Q30544631-1961A06D-0652-4FC9-A1EB-C4520ED52732

P407

Q30544631-AF59DBC4-F619-4285-9D6F-B4E95EF32268

P433

Q30544631-CBCF7941-2817-4A9D-A902-22C868FBB0D4

P478

Q30544631-B3453953-921B-44CA-8BF8-D140B88F5D5D

P50

Q30544631-3EFD4BCE-ADC6-43BF-9CCE-7B2F3E6E5F54

Q30544631-42870971-CBA1-49C5-87DF-19CF1596D9C2

P577

Q30544631-3B8CB987-DFCD-4DFC-B5B5-8BAD9B3A3EAA

P5875

Q30544631-9627EF65-C496-4894-97C5-9221271D9CF7

P698

Q30544631-430D0682-1288-4676-A098-BA4D25B69D0C

P921

Q30544631-161F1551-E28F-4177-8B45-77FC6C0E59CC

P932

Q30544631-391A263F-A852-41D4-A221-DC3C1F23E7B3

P356

JCO.2013.51.1816

P1433

Journal of Clinical Oncology

P1476

Gefitinib versus placebo in co ...... lts of the NCIC CTG BR19 study

@en

P2093

Charles Butts

http://www.w3.org/2001/XMLSchema#string

Chris O'Callaghan

http://www.w3.org/2001/XMLSchema#string

Fadlo Khuri

http://www.w3.org/2001/XMLSchema#string

Frances A Shepherd

http://www.w3.org/2001/XMLSchema#string

Glenwood D Goss

http://www.w3.org/2001/XMLSchema#string

Gregory A Masters

http://www.w3.org/2001/XMLSchema#string

Hak Choy

http://www.w3.org/2001/XMLSchema#string

Ian Lorimer

http://www.w3.org/2001/XMLSchema#string

James Jett

http://www.w3.org/2001/XMLSchema#string

Joan Schiller

http://www.w3.org/2001/XMLSchema#string

P2860

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Revisions in the International System for Staging Lung Cancer

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

Erlotinib in previously treated non-small-cell lung cancer

Screening for epidermal growth factor receptor mutations in lung cancer

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.

P304

3320-3326

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2013.51.1816

http://www.w3.org/2001/XMLSchema#string

P407

P433

27

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Ming-Sound Tsao

David R Gandara

P577

2013-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256120344

http://www.w3.org/2001/XMLSchema#string

P698

23980091

http://www.w3.org/2001/XMLSchema#string

P921

P932

3770864

http://www.w3.org/2001/XMLSchema#string